{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:24:20Z","timestamp":1780615460666,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.phrs.2013.10.007","type":"journal-article","created":{"date-parts":[[2013,11,13]],"date-time":"2013-11-13T20:15:50Z","timestamp":1384373750000},"page":"74-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Vasopressin receptors and pharmacological chaperones: From functional rescue to promising therapeutic strategies"],"prefix":"10.1016","volume":"83","author":[{"given":"Bernard","family":"Mouillac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Mendre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2013.10.007_bib0005","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/00000542-200609000-00026","article-title":"The vasopressin system","volume":"105","author":"Treschan","year":"2006","journal-title":"Anesthesiology"},{"key":"10.1016\/j.phrs.2013.10.007_bib0010","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1210\/er.2012-1044","article-title":"Nephrogenic diabetes insipidus: essential insights into the molecular background and potential therapies for treatment","volume":"34","author":"Moeller","year":"2013","journal-title":"Endocr Rev"},{"key":"10.1016\/j.phrs.2013.10.007_bib0015","doi-asserted-by":"crossref","first-page":"27849","DOI":"10.1074\/jbc.M112.445098","article-title":"Noncanonical control of vasopressin receptor type 2 signaling by retromer and arrestin","volume":"288","author":"Feinstein","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.10.007_bib0020","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1146\/annurev.physiol.63.1.607","article-title":"Nephrogenic diabetes insipidus","volume":"63","author":"Morello","year":"2001","journal-title":"Ann Rev Physiol"},{"key":"10.1016\/j.phrs.2013.10.007_bib0025","first-page":"278","article-title":"Nature and recurrence of AVPR2 mutations in X-linked nephrogenic diabetes insipidus","volume":"55","author":"Bichet","year":"1994","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.phrs.2013.10.007_bib0030","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1172\/JCI118252","article-title":"Binding, intracellular transport and biosynthesis-defective mutants of vasopressin type 2 receptor in patients with X-linked nephrogenic diabetes insipidus","volume":"96","author":"Tsukagushi","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.phrs.2013.10.007_bib0035","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1681\/ASN.V9101861","article-title":"Functional studies of twelve mutant V2 vasopressin receptors related to nephrogenic diabetes insipidus: molecular basis of a mild clinical phenotype","volume":"9","author":"Ala","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.phrs.2013.10.007_bib0040","article-title":"Urinary concentration: different ways to open and close the tap","author":"Bockenhauer","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.phrs.2013.10.007_bib0045","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/357333a0","article-title":"Molecular cloning of the receptor for human antidiuretic hormone","volume":"357","author":"Birnbaumer","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2013.10.007_bib0050","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/357336a0","article-title":"Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus","volume":"357","author":"Lolait","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2013.10.007_bib0055","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/359233a0","article-title":"Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidus","volume":"359","author":"Rosenthal","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2013.10.007_bib0060","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1172\/JCI2303","article-title":"Defective aquaporin-2 trafficking in nephrogenic diabetes insipidus and correction by chemical chaperones","volume":"101","author":"Tamarappoo","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.phrs.2013.10.007_bib0065","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1074\/jbc.272.2.709","article-title":"Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulars","volume":"272","author":"Loo","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.10.007_bib0070","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1172\/JCI8688","article-title":"Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants","volume":"105","author":"Morello","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.phrs.2013.10.007_bib0075","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0165-6147(00)01575-3","article-title":"Pharmacological chaperones: a new twist on receptor folding","volume":"21","author":"Morello","year":"2000","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.phrs.2013.10.007_bib0080","doi-asserted-by":"crossref","first-page":"35678","DOI":"10.1074\/jbc.M301888200","article-title":"Appropriate polarization following pharmacological rescue of V2 vasopressin receptors encoded by X-linked nephrogenic diabetes insipidus alleles involves a conformation of the receptor that also attains mature glycosylation","volume":"278","author":"Tan","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.10.007_bib0085","doi-asserted-by":"crossref","first-page":"47254","DOI":"10.1074\/jbc.M408154200","article-title":"Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors","volume":"279","author":"W\u00fcller","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.10.007_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000245059","article-title":"Vasopressin type 2 receptor V88M mutation: molecular basis of partial and complete nephrogenic diabetes insipidus","volume":"114","author":"Bockenhauer","year":"2010","journal-title":"Nephron Physiol"},{"key":"10.1016\/j.phrs.2013.10.007_bib0165","doi-asserted-by":"crossref","first-page":"e22784","DOI":"10.1371\/journal.pone.0022784","article-title":"Therapeutic rescue of misfolded mutants: validation of primary high throughput screens for identification of pharmacoperone drugs","volume":"6","author":"Janovick","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2013.10.007_bib0100","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1210\/me.2004-0080","article-title":"Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR 49059","volume":"18","author":"Bernier","year":"2004","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.phrs.2013.10.007_bib0105","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1681\/ASN.2005080854","article-title":"Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus","volume":"17","author":"Bernier","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.phrs.2013.10.007_bib0110","doi-asserted-by":"crossref","first-page":"F253","DOI":"10.1152\/ajprenal.00247.2006","article-title":"Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus","volume":"292","author":"Robben","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.phrs.2013.10.007_bib0115","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1091\/mbc.E05-06-0579","article-title":"Rescue of vasopressin V2 receptor mutants by chemical chaperones: specificity and mechanism","volume":"17","author":"Robben","year":"2006","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.phrs.2013.10.007_bib0120","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1210\/jcem.87.7.8582","article-title":"Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target","volume":"87","author":"Janovick","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.phrs.2013.10.007_bib0125","doi-asserted-by":"crossref","first-page":"42198","DOI":"10.1074\/jbc.M510180200","article-title":"Mechanisms of cell-surface rerouting of an endoplasmic reticulum-retained mutant of the vasopressin V1b\/V3 receptor by a pharmacological chaperone","volume":"280","author":"Auzan","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.10.007_bib0130","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1074\/jbc.M511610200","article-title":"Pharmacological chaperone activity of SR 49059 to functionally recover misfolded mutations of the vasopressin V1a receptor","volume":"281","author":"Hawtin","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.10.007_bib0135","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1051\/medsci\/2010266-7627","article-title":"Pharmacological chaperones: a potential therapeutic treatment for conformational diseases","volume":"26","author":"Mendre","year":"2010","journal-title":"Med Sci (Paris)"},{"key":"10.1016\/j.phrs.2013.10.007_bib0140","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1365-2826.2010.01983.x","article-title":"Potential of nonpeptide (ant)agonists to rescue vasopressin V2 receptor mutants for the treatment of X-linked nephrogenic diabetes insipidus","volume":"22","author":"Los","year":"2010","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.phrs.2013.10.007_bib0145","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1007\/s00467-012-2118-8","article-title":"Congenital nephrogenic diabetes insipidus: the current state of affairs","volume":"27","author":"Wesche","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.phrs.2013.10.007_bib0150","doi-asserted-by":"crossref","first-page":"12195","DOI":"10.1073\/pnas.0900130106","article-title":"Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists","volume":"106","author":"Robben","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.phrs.2013.10.007_bib0155","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1681\/ASN.2008121289","article-title":"Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital nephrogenic diabetes insipidus","volume":"20","author":"Jean-Alphonse","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.phrs.2013.10.007_bib0160","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.tips.2012.11.006","article-title":"Novel pharmacological strategies to treat cystic fibrosis","volume":"34","author":"Hanrahan","year":"2013","journal-title":"Trends Pharmacol Sci"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661813001758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661813001758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T06:48:09Z","timestamp":1647067689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661813001758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":32,"alternative-id":["S1043661813001758"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2013.10.007","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vasopressin receptors and pharmacological chaperones: From functional rescue to promising therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2013.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}